Ironwood Pharmaceuticals

IRWD · NASDAQ

$3.63+$0.07 (+1.97%)TodayMarket closed · Oct 20, 7:45 PM ET

Prev close $3.56

Latest news

Press releaseOct 16, 7:30 AM ETBusiness Wire
Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer
NewsOct 5, 9:08 AM ET
Ironwood Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript
Press releaseSep 3, 4:05 PM ETBusiness Wire
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
NewsAug 6, 7:09 AM ET
Ironwood Pharmaceuticals Q2 Adj. EPS $0.31 Misses $0.36 Estimate, Sales $113.041M Miss $114.844M Estimate
Press releaseAug 6, 7:05 AM ETBusiness Wire
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
Press releaseJul 30, 4:05 PM ETBusiness Wire
Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call
NewsJul 14, 7:32 AM ET
Ironwood Pharma Initiates Phase 3 STARS‑2 Trial Of Apraglutide In Short Bowel Syndrome With Intestinal Failure
Press releaseJul 14, 7:30 AM ETBusiness Wire
Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
Press releaseMay 28, 4:05 PM ETBusiness Wire
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Press releaseMay 27, 10:00 AM ETBusiness Wire
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
NewsMay 7, 7:07 AM ET
Ironwood Pharmaceuticals Q1 Adj. EPS $0.24, Inline, Sales $106.506M Beat $92.088M Estimate
Press releaseMay 7, 7:05 AM ETBusiness Wire
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
Press releaseMay 4, 7:05 AM ETBusiness Wire
Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
Press releaseApr 30, 4:05 PM ETBusiness Wire
Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call
Press releaseApr 23, 7:05 AM ETBusiness Wire
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
Press releaseMar 4, 4:05 PM ETBusiness Wire
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
NewsFeb 25, 12:05 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsFeb 25, 7:06 AM ET
Ironwood Pharmaceuticals Q4 Adj. EPS $(0.01) Misses $0.01 Estimate, Sales $47.709M Miss $50.933M Estimate
Press releaseFeb 25, 7:05 AM ETBusiness Wire
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
NewsFeb 25, 6:11 AM ET
Earnings Scheduled For February 25, 2026
NewsFeb 24, 2:03 PM ET
Insights into Ironwood Pharmaceuticals's Upcoming Earnings
Press releaseFeb 18, 4:21 PM ETBusiness Wire
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call
NewsJan 5, 8:36 AM ETRishabh Mishra
Stock Market Today: S&P 500, Nasdaq, WTI Crude Futures Advance After US Strike On Venezuela— GH Research, Vertiv Holdings, Nukkleus In Focus (UPDATED)
NewsJan 2, 12:23 PM ETAvi Kapoor
Why Intelligent Bio Solutions Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
NewsJan 2, 12:13 PM ETAvi Kapoor
Crude Oil Falls 1%; US Manufacturing Growth Eases In December
NewsJan 2, 9:45 AM ETAvi Kapoor
US Stocks Mixed; Dow Falls Over 100 Points
Press releaseJan 2, 7:05 AM ETBusiness Wire
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
NewsNov 26, 11:30 AM ETAvi Kapoor
Urban Outfitters, Arrowhead Pharmaceuticals, Petco Health and Wellness And Other Big Stocks Moving Higher On Wednesday
NewsNov 10, 12:07 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
Press releaseNov 10, 7:05 AM ETBusiness Wire
Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance
NewsNov 5, 11:33 AM ET
FDA Approved Linzess Capsules For Pediatric Patients 7 Years And Older With Irritable Bowel Syndrome With Constipation; Linzess Recommended Dosage For Pediatric Patients 7 Years And Older With IBS-C Is 145 mcg Orally Once Daily
NewsSep 4, 5:42 AM ETAvi Kapoor
Why American Eagle Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
NewsAug 7, 8:07 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Press releaseAug 7, 7:05 AM ETBusiness Wire
Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance
Press releaseMay 7, 7:05 AM ETBusiness Wire
Ironwood Pharmaceuticals Reports First Quarter 2025 Results
Press releaseApr 30, 4:25 PM ETBusiness Wire
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
Press releaseApr 25, 7:05 AM ETBusiness Wire
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
Press releaseApr 22, 4:05 PM ETBusiness Wire
Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support
NewsApr 14, 12:37 PM ETAvi Kapoor
Crude Oil Moves Lower; M&T Bank Earnings Miss Views
NewsApr 14, 9:48 AM ETAvi Kapoor
Nasdaq Surges 2%; Goldman Sachs Posts Upbeat Earnings

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer

Ironwood Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript

Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference

Ironwood Pharmaceuticals Q2 Adj. EPS $0.31 Misses $0.36 Estimate, Sales $113.041M Miss $114.844M Estimate

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call

Ironwood Pharma Initiates Phase 3 STARS‑2 Trial Of Apraglutide In Short Bowel Syndrome With Intestinal Failure

Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients

Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

Ironwood Pharmaceuticals Q1 Adj. EPS $0.24, Inline, Sales $106.506M Beat $92.088M Estimate

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)

Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

12 Health Care Stocks Moving In Wednesday's Intraday Session

Ironwood Pharmaceuticals Q4 Adj. EPS $(0.01) Misses $0.01 Estimate, Sales $47.709M Miss $50.933M Estimate

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook

Earnings Scheduled For February 25, 2026

Insights into Ironwood Pharmaceuticals's Upcoming Earnings

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call

Stock Market Today: S&P 500, Nasdaq, WTI Crude Futures Advance After US Strike On Venezuela— GH Research, Vertiv Holdings, Nukkleus In Focus (UPDATED)

Why Intelligent Bio Solutions Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Crude Oil Falls 1%; US Manufacturing Growth Eases In December

US Stocks Mixed; Dow Falls Over 100 Points

Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance

Urban Outfitters, Arrowhead Pharmaceuticals, Petco Health and Wellness And Other Big Stocks Moving Higher On Wednesday

12 Health Care Stocks Moving In Monday's Intraday Session

Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance

FDA Approved Linzess Capsules For Pediatric Patients 7 Years And Older With Irritable Bowel Syndrome With Constipation; Linzess Recommended Dosage For Pediatric Patients 7 Years And Older With IBS-C Is 145 mcg Orally Once Daily

Why American Eagle Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance

Ironwood Pharmaceuticals Reports First Quarter 2025 Results

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance

Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support

Crude Oil Moves Lower; M&T Bank Earnings Miss Views

Nasdaq Surges 2%; Goldman Sachs Posts Upbeat Earnings